See more : Novagant Corp. (NVGT) Income Statement Analysis – Financial Results
Complete financial analysis of Sonnet BioTherapeutics Holdings, Inc. (SONN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sonnet BioTherapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kane Biotech Inc. (KNBIF) Income Statement Analysis – Financial Results
- Shristi Infrastructure Development Corporation Limited (SHRISTI.BO) Income Statement Analysis – Financial Results
- Downer EDI Ltd (DOW.NZ) Income Statement Analysis – Financial Results
- PWR Holdings Limited (PWRHF) Income Statement Analysis – Financial Results
- Sanaby Health Acquisition Corp. I (SANBW) Income Statement Analysis – Financial Results
Sonnet BioTherapeutics Holdings, Inc. (SONN)
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.63K | 147.81K | 349.94K | 483.63K | 0.00 | 40.61M | 30.73M | 41.43M | 41.70M | 42.40M | 0.00 | 17.50M | 6.88M | 1.46M | 136.30K | 684.68K | 234.06K |
| Cost of Revenue | 0.00 | 11.81M | 93.26K | 16.63M | 58.31K | 7.93M | 29.94M | 39.41M | 38.38M | 14.04M | 0.00 | 0.00 | 2.76M | 360.81K | 11.08K | 684.68K | 234.06K |
| Gross Profit | 18.63K | -11.67M | 256.69K | -16.15M | -58.31K | 32.68M | 791.11K | 2.03M | 3.33M | 28.36M | 0.00 | 17.50M | 4.12M | 1.10M | 125.22K | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -7,893.43% | 73.35% | -3,339.55% | 0.00% | 80.47% | 2.57% | 4.89% | 7.98% | 66.89% | 0.00% | 100.00% | 59.87% | 75.35% | 91.87% | 0.00% | 0.00% |
| Research & Development | 5.74M | 11.81M | 21.44M | 16.63M | 9.88M | 2.20M | 154.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 363.88K | 4.55M | 5.80M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.50M | 0.00 | 145.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 3.86M | 4.55M | 5.95M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 935.11K | 2.24M | 2.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 125.50K | 0.00 | 11.05M | 11.05M | 5.19M | 3.45M | 3.36M | 0.00 | -23.29M | 0.00 | 0.00 | 0.00 | -1.12M | -1.14M |
| Operating Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 3.86M | 4.55M | 5.95M | 10.78M | 0.00 | -23.29M | 2.62M | 1.25M | 935.11K | 1.12M | 1.14M |
| Cost & Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 33.80M | 43.95M | 44.32M | 24.82M | 0.00 | -23.29M | 9.75M | 2.18M | 946.19K | 1.13M | 1.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 15.00 | 20.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.54K | 46.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 20.68K | 162.87K | 381.68K | -2.59M | -2.35M | -3.47M | 0.00 | 0.00 | -474.93K | -180.83K | 140.02K | 33.91K | 20.49K |
| Depreciation & Amortization | 0.00 | 75.75K | 93.26K | 95.16K | 58.31K | 3.54M | 1.82M | 2.28M | 2.34M | 2.36M | 0.00 | 0.00 | 383.45K | 87.62K | 11.08K | 11.48K | 11.20K |
| EBITDA | -11.85M | -18.72M | -29.58M | -24.99M | -24.24M | -13.15M | -3.71M | -2.93M | 541.15K | -2.73M | 0.00 | -3.91M | -3.24M | -1.18M | -878.82K | -376.05K | -2.21M |
| EBITDA Ratio | -63,617.91% | -12,663.22% | -8,463.34% | -5,163.13% | 0.00% | -11.59% | -4.08% | -0.57% | -0.67% | -31.68% | 0.00% | -33.13% | -47.06% | -80.75% | -644.76% | -54.92% | -942.91% |
| Operating Income | -11.85M | -18.79M | -29.67M | -25.09M | -24.24M | -4.71M | -3.07M | -2.52M | -2.62M | -11.49M | 0.00 | -5.80M | -2.87M | -714.31K | -809.89K | -444.49K | -949.99K |
| Operating Income Ratio | -63,617.91% | -12,714.47% | -8,478.34% | -5,187.36% | 0.00% | -11.59% | -9.99% | -6.08% | -6.28% | -27.10% | 0.00% | -33.13% | -41.69% | -48.80% | -594.19% | -64.92% | -405.88% |
| Total Other Income/Expenses | 4.41M | -40.08K | -52.48K | 103.48K | -27.34K | -162.87K | -7.38M | -5.29M | -1.53M | 3.59M | 0.00 | 508.78K | -505.46K | -379.90K | -220.03K | -369.21K | -1.29M |
| Income Before Tax | -7.44M | -18.83M | -29.72M | -24.98M | -24.27M | -4.87M | -8.07M | -7.81M | -4.15M | -14.32M | 0.00 | -5.96M | -3.38M | -1.09M | -1.03M | -813.70K | -2.24M |
| Income Before Tax Ratio | -39,929.30% | -12,741.58% | -8,493.34% | -5,165.97% | 0.00% | -11.99% | -26.26% | -18.85% | -9.95% | -33.78% | 0.00% | -34.07% | -49.04% | -74.75% | -755.62% | -118.84% | -956.45% |
| Income Tax Expense | 0.00 | 0.00 | 52.48K | 22.03K | 6.80M | 162.87K | -701.22K | -644.43K | 198.46K | -187.57K | 0.00 | 0.00 | 19.21K | 14.61K | 0.00 | 0.00 | 0.00 |
| Net Income | -7.44M | -18.83M | -29.77M | -25.01M | -31.06M | -5.03M | -6.85M | -6.79M | -9.08M | -12.14M | 0.00 | -5.96M | -3.17M | -1.10M | -1.01M | -813.70K | -2.24M |
| Net Income Ratio | -39,929.30% | -12,741.58% | -8,508.34% | -5,170.52% | 0.00% | -12.40% | -22.30% | -16.40% | -21.77% | -28.63% | 0.00% | -34.07% | -46.01% | -75.38% | -742.16% | -118.84% | -956.45% |
| EPS | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| EPS Diluted | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| Weighted Avg Shares Out | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
| Weighted Avg Shares Out (Dil) | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company's recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the pricing of an underwritten public offering of 1,111,111 shares of common...
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it received notice on October 16, 2024 from The Nasdaq Stock Market...
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
Sonnet to receive $1.0 million in upfront payment and up to an additional $1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India market
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it has received preliminary approval for a tax credit from the New Jersey...
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stock split of its outstanding...
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot' Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company”...
Source: https://incomestatements.info
Category: Stock Reports